Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

4.530 -0.040 (-0.88%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 26, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 26, 2025

Via Benzinga

Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗

June 26, 2025

Via Benzinga

Altimmune Stock Runs Hot Ahead Of MASH Trial Readout; Retail Bulls Eye Big Win ↗

June 25, 2025

Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape.

Via Stocktwits

What to Expect from Altimmune's Earnings ↗

May 12, 2025

Via Benzinga

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

March 03, 2025

Via Benzinga

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. ↗

June 18, 2025

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

June 10, 2025

Via Benzinga

Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? ↗

May 20, 2025

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement.

Via Benzinga

Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased ↗

May 13, 2025

In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).

Via Stocktwits

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

January 23, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 05, 2025

Via Benzinga

What's Going On With Altimmune (ALT) Stock Today? ↗

May 02, 2025

Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress.

Via Benzinga

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? ↗

April 30, 2025

Via The Motley Fool

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗

April 14, 2025

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

Via Benzinga

8 Analysts Assess Altimmune: What You Need To Know ↗

April 03, 2025

Via Benzinga

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move ↗

March 22, 2025

Via The Motley Fool

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon ↗

March 19, 2025

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Via Stocktwits

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders ↗

March 14, 2025

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

Via Benzinga

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

February 28, 2025

Via Benzinga

Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print ↗

February 27, 2025

The company plans to unveil details at its virtual R&D Day on March 13.

Via Stocktwits

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

January 08, 2025

Via Benzinga

Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore ↗

December 20, 2024

The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.

Via Talk Markets

Topics Stocks / Equities

Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

December 04, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday ↗

November 12, 2024

Via Benzinga

This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

November 12, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Altimmune, Inc. - Common Stock (NQ:ALT)

Headline News about Altimmune, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today